Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
Phase 3
Completed
- Conditions
- HIV InfectionsHIV Seronegativity
- Registration Number
- NCT00006327
- Lead Sponsor
- VaxGen
- Brief Summary
The purpose of this study is to determine if the vaccine, AIDSVAX B/E, will protect intravenous drug users from becoming infected with HIV.
- Detailed Description
Volunteers are immunized and followed for a minimum of 2 years. Any volunteer that becomes infected with HIV-1 is followed every 4 months post infection for up to 36 months. Behavior effects associated with study participation are assessed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2500
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which AIDSVAX B/E induces immune responses in intravenous drug users?
How does the efficacy of AIDSVAX B/E compare to standard-of-care HIV prevention strategies in high-risk populations?
Which biomarkers correlate with protection against HIV-1 infection in the AIDSVAX B/E clinical trial NCT00006327?
What adverse events were reported in the Phase III AIDSVAX B/E trial and how were they managed in HIV seronegative participants?
Are there combination approaches involving AIDSVAX B/E and antiretroviral therapies for HIV prevention in intravenous drug users?
Trial Locations
- Locations (1)
Kachit Choopanya
🇹🇭Klongsan / Bangkok, Thailand
Kachit Choopanya🇹🇭Klongsan / Bangkok, Thailand